Pfizer
Pfizer secures China nod for obesity drug as generics loom
Pfizer now enters a field dominated by multinational rivals
Pfizer beats Q4 profit estimates on strong drug demand
Robust demand for its heart and oncology drugs helped achieve total sales for the quarter of US$17.56 billion
Pfizer forecasts 2026 profit below expectations on lower Covid product sales
Pfizer has rolled out a sweeping cost reduction programme in response to the drop in Covid-19 sales
Pfizer looks to sell stake in pandemic vaccine partner BioNTech
The stake sale could be worth about US$508 million for Pfizer
Metsera accepts Pfizer’s US$10 billion bid in ongoing M&A battle
OBESITY drug developer Metsera said on Friday that it had accepted Pfizer’s US$10 billion acquisition offer, in what could spell the end of a bidding war between the New York-based pharma giant and ri...
Pfizer boosts profit view as it battles for obesity startup
Its adjusted earnings for the year will be US$3 a share to US$3.15 a share
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid
[BENGALURU] Pfizer on Friday (Oct 31) filed a lawsuit against Metsera and Novo Nordisk, saying Metsera breached its merger agreement obligations in declaring the Danish drugmaker’s US$8.5 billion bid ...
The Pfizer-Trump deal: A new chapter in drug pricing or political theatre?
The approach may generate headlines while leaving the structural problems of American pharmaceutical pricing unaddressed
Pfizer’s drug price cuts yield three-year Trump tariff reprieve
The US president has repeatedly pressured companies to bring their US prices in line with what foreign countries pay
Why China biotech is getting a DeepSeek moment, too
The country is emerging as an attractive place for Big Pharma to chase billion-dollar licensing deals
